Royalty Pharma plc Financial Ratios — RPRX Stock

Profitability (USD)

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
As of date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025

Return on Common Equity (%)	- -	61.25	44.29	24.29	29.68	2.03	50.63	32.03	29.64
Return on Assets (%)	- -	24.23	19.72	6.85	3.7	0.25	6.84	4.96	4.07
Return on Capital (%)	- -	27.39	21.35	3.22	1.23	0.33	6.01	4.7	3.7
Return on Invested Capital (%)	- -	24.65	22.37	11.82	8.66	5.43	9.08	7.56	8.52
Gross Margin (%)	100	100	100	100	100	100	100	100	100
EBITDA Margin (%)	60.89	77.87	145.91	79.32	63.5	41.51	63.37	57.1	65.74
Operating Margin (%)	58.81	76.02	144.59	78.24	62.49	41.25	63.37	57.1	65.58
Incremental Operating Margin (%)	- -	215.65	6,501.7	-312.47	-137.48	971.95	485.14	219.51	233.01
Pretax Margin (%)	84.06	84.57	135.67	80.19	54.21	10.28	72.2	58.79	55.68
Profit Margin (%)	75.72	76.76	129.45	45.94	27.07	1.91	48.2	37.95	32.42
Net Income to Common Margin (%)	75.72	76.76	129.45	45.94	27.07	1.91	48.2	37.95	32.42
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Dvd Payout Ratio (%)	49.8	49.12	28.72	16.38	15.31	79.88	15.82	20.88	20.15
Sustainable Growth Rate (%)	- -	31.17	31.57	20.31	25.14	0.41	42.62	25.34	23.67

Credit (USD)

MCP API Chat

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
As of date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025

Total Debt	- -	6,519	6,238	5,817	7,096	7,116	6,135	7,612	8,951
ST Debt	- -	281	282	- -	- -	998	- -	998	380
LT Debt	- -	6,238	5,956	5,817	7,096	6,119	6,135	6,615	8,571
Total Debt/EBITDA	- -	4.66	2.36	3.46	4.88	7.66	4.11	5.89	5.73
Net Debt/EBITDA	- -	3.29	2.26	2.86	3.82	5.82	3.79	5.17	5.33
Total Debt/EBIT	- -	4.78	2.38	3.5	4.96	7.71	4.11	5.89	5.74
Net Debt/EBIT	- -	3.37	2.28	2.9	3.88	5.86	3.79	5.17	5.34
EBITDA to Interest Expense	3.93	4.99	9.86	10.72	8.75	4.94	7.97	5.73	5.08
EBITDA-CapEx/Interest Expense	3.93	4.99	9.86	10.72	8.75	4.94	7.97	5.73	5.08
EBIT to Interest Expense	3.8	4.87	9.77	10.57	8.61	4.91	7.97	5.73	5.07
Interest Expense	247	280	269	157	166	188	187	226	308
Common Equity/Total Assets	- -	39.56	49.06	11.99	12.88	11.69	15.37	15.62	12.01
Long-Term Debt/Equity (%)	- -	137.03	96.98	58.78	69.24	64.24	60.84	63.96	88.22
Long-Term Debt/Capital (%)	- -	56.29	48.1	45.39	51.33	47.15	50.24	47.75	58.93
Long-Term Debt/Total Assets (%)	- -	54.86	47.84	36.31	40.51	36.39	37.45	36.3	43.68
Total Debt/Equity (%)	- -	143.22	101.57	58.78	69.24	74.71	60.84	73.6	92.14
Total Debt/Capital (%)	- -	58.83	50.38	45.39	51.33	54.83	50.24	54.95	61.54
Total Debt/Total Assets (%)	- -	57.34	50.11	36.31	40.51	42.33	37.45	41.77	45.62
Net Debt to Equity	- -	100.95	97.57	48.59	54.2	56.75	56.11	64.62	85.77
Net Debt/Capital (%)	- -	50.18	49.38	40.73	45.23	47.97	48.22	51.71	59.83
EBITDA	973	1,398	2,647	1,684	1,454	929	1,492	1,292	1,563
EBITDA-CapEx	973	1,398	2,647	1,684	1,454	929	1,492	1,292	1,563
Operating Income (Loss)	940	1,364	2,623	1,660	1,431	923	1,492	1,292	1,560

Liquidity (USD)

MCP API Chat

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
As of date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025

Cash Ratio	- -	4.11	2.38	8.6	16.37	2.08	7.65	1.41	2.34
Current Ratio	- -	4.5	2.5	8.76	16.81	2.19	7.9	1.44	2.4
Quick Ratio	- -	4.45	2.5	8.73	16.77	2.11	7.78	1.43	2.39
CFO/Avg Current Liab	- -	5.58	3.65	6.35	8.42	3.2	4.5	3.91	2.63
Common Equity/Total Assets	- -	39.56	49.06	11.99	12.88	11.69	15.37	15.62	12.01
Long-Term Debt/Equity (%)	- -	137.03	96.98	58.78	69.24	64.24	60.84	63.96	88.22
Long-Term Debt/Capital (%)	- -	56.29	48.1	45.39	51.33	47.15	50.24	47.75	58.93
Long-Term Debt/Total Assets (%)	- -	54.86	47.84	36.31	40.51	36.39	37.45	36.3	43.68
Total Debt/Equity (%)	- -	143.22	101.57	58.78	69.24	74.71	60.84	73.6	92.14
Total Debt/Capital (%)	- -	58.83	50.38	45.39	51.33	54.83	50.24	54.95	61.54
Total Debt/Total Assets (%)	- -	57.34	50.11	36.31	40.51	42.33	37.45	41.77	45.62
CFO/Total Liabilities	- -	23.74	26.43	33.22	27.76	29.42	47.44	35.14	25.13
CFO/CapEx	- -	- -	- -	- -	- -	- -	- -	- -	- -
Altman's Z-Score	- -	0.92	1.21	2.73	2.13	2	1.94	1.48	1.64

Working Capital (USD)

MCP API Chat

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
As of date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025

Accounts Receivable Turnover	- -	- -	- -	- -	- -	- -	- -	- -	- -
Days Sales Outstanding	- -	- -	- -	- -	- -	- -	- -	- -	- -
Inventory Turnover	- -	- -	- -	- -	- -	- -	- -	- -	- -
Days Inventory Outstanding	- -	- -	- -	- -	- -	- -	- -	- -	- -
Accounts Payable Turnover	- -	- -	- -	- -	- -	- -	- -	- -	- -
Accounts Payable Turnover Days	- -	- -	- -	- -	- -	- -	- -	- -	- -
Cash Conversion Cycle	- -	- -	- -	- -	- -	- -	- -	- -	- -
Inventory to Cash Days	- -	- -	- -	- -	- -	- -	- -	- -	- -
Inventories	- -	- -	- -	- -	- -	- -	- -	- -	- -
Raw Materials	- -	- -	- -	- -	- -	- -	- -	- -	- -
Work In Process	- -	- -	- -	- -	- -	- -	- -	- -	- -
Finished Goods	- -	- -	- -	- -	- -	- -	- -	- -	- -
Other Inventory	- -	- -	- -	- -	- -	- -	- -	- -	- -

Enterprise Value (USD)

MCP API Chat

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
As of date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025

Market Capitalization	- -	- -	- -	19,426	16,530	17,308	12,573	11,377	16,564
- Cash & Cash Equivalents	- -	1,924	246	1,009	1,541	1,711	477	929	619
+ Preferred Equity and Hybrid Capital	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Minority/Non Controlling Interest	- -	64	36	5,077	4,472	3,897	3,558	3,396	3,238
+ Total Debt	- -	6,519	6,238	5,817	7,096	7,116	6,135	7,612	8,951
Enterprise Value	- -	4,197	5,481	27,671	25,294	25,894	21,032	20,614	27,261
Total Capital	- -	11,082	12,382	12,814	13,823	12,978	12,211	13,854	14,545
Total Debt/Capital (%)	- -	58.83	50.38	45.39	51.33	54.83	50.24	54.95	61.54
Total Debt / EV	- -	1.55	1.14	0.21	0.28	0.27	0.29	0.37	0.33
EV/Sales	- -	2.34	3.02	13.04	11.05	11.57	8.93	9.11	11.46
EV/EBITDA	- -	3	2.07	16.44	17.4	27.89	14.1	15.95	17.44
EV/EBIT	- -	3.08	2.09	16.66	17.68	28.06	14.1	15.95	17.48
EV/Cash Flow to Firm	- -	2.21	2.83	12.63	11.58	11.1	6.62	6.88	9.74
EV/Free Cash Flow to Firm	- -	2.21	2.83	12.63	11.58	11.1	6.62	6.88	9.74
Diluted Market Cap	- -	- -	- -	19,426	16,530	17,309	16,935	15,153	21,793
Diluted Enterprise Value	- -	4,659	6,028	29,311	26,557	26,611	26,152	25,232	33,363
EV per Share	- -	11.85	15.47	71.29	60.98	59.12	46.99	46.22	63.59
TTM Sales	1,598	1,795	1,814	2,122	2,289	2,237	2,355	2,264	2,378
TTM EBITDA	973	1,398	2,647	1,684	1,454	929	1,492	1,292	1,563
TTM Operating Income	940	1,364	2,623	1,660	1,431	923	1,492	1,292	1,560
TTM Cash Flow to Firm	1,666	1,898	1,936	2,192	2,184	2,332	3,175	2,994	2,797
TTM Free Cash Flow to Firm	1,666	1,898	1,936	2,192	2,184	2,332	3,175	2,994	2,797

Multiples (USD)

MCP API Chat

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
As of date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025

Price/Free Cash Flow	- -	- -	- -	9.55	8.19	8.07	5.67	5.47	8.75
EV/EBIT	- -	3.08	2.09	16.66	17.68	28.06	14.1	15.95	17.48
Enterprise Value	- -	4,197	5,481	27,671	25,294	25,894	21,032	20,614	27,261
Low Price	- -	- -	- -	34.8	34.86	36.15	25.92	24.05	25.4
EV/Sales	- -	2.34	3.02	13.04	11.05	11.57	8.93	9.11	11.46
EV/EBITDA	- -	3	2.07	16.44	17.4	27.89	14.1	15.95	17.44
Price/Earnings	- -	- -	- -	19.92	26.67	404.1	11.08	13.24	21.48
Price/Earnings Average	- -	- -	- -	17.2	28.01	421.2	12.62	14.45	19.38
Price/Earnings High	- -	- -	- -	22.49	35.63	457.57	15.75	16.44	22.93
Price/Earnings Low	- -	- -	- -	13.85	23.33	369.64	10.22	12.49	14.12
Price/Book Value	- -	- -	- -	10.11	7.33	8.81	4.99	4	7.03
Price/Book Value Average	- -	- -	- -	8.73	7.7	9.18	5.69	4.36	6.34
Price/Book Value High	- -	- -	- -	11.42	9.79	9.98	7.1	4.96	7.5
Price/Book Value Low	- -	- -	- -	7.03	6.41	8.06	4.61	3.77	4.62
Price/Tangible Book Value	- -	- -	- -	1.97	1.61	1.82	1.25	1.1	1.88
Price/Tangible Book Value Average	- -	- -	- -	1.7	1.69	1.89	1.42	1.2	1.7
Price/Tangible Book Value High	- -	- -	- -	2.22	2.16	2.06	1.77	1.37	2.01
Price/Tangible Book Value Low	- -	- -	- -	1.37	1.41	1.66	1.15	1.04	1.24
Price/Sales	- -	- -	- -	9.15	7.22	7.74	5.34	5.03	6.96
Price/Sales Average	- -	- -	- -	7.9	7.58	8.06	6.08	5.48	6.28
Price/Sales High	- -	- -	- -	10.33	9.64	8.76	7.59	6.24	7.43
Price/Sales Low	- -	- -	- -	6.36	6.32	7.08	4.93	4.74	4.58
Price/Cash Flow	- -	- -	- -	9.55	8.19	8.07	4.21	4.11	6.65
Price/Cash Flow Average	- -	- -	- -	8.24	8.6	8.41	4.79	4.48	6
Price/Cash Flow High	- -	- -	- -	10.78	10.94	9.14	5.98	5.1	7.1
Price/Cash Flow Low	- -	- -	- -	6.64	7.17	7.38	3.88	3.87	4.37
Price/Free Cash Flow Average	- -	- -	- -	8.24	8.6	8.41	6.46	5.97	7.9
Price/Free Cash Flow High	- -	- -	- -	10.78	10.94	9.14	8.06	6.79	9.34
Price/Free Cash Flow Low	- -	- -	- -	6.64	7.17	7.38	5.23	5.16	5.75
EV/Sales Average	- -	2.6	3.32	12.56	11.96	12.22	10	9.94	11.15
EV/Sales High	- -	2.6	3.32	14.99	14.02	12.92	11.5	10.69	12.3
EV/Sales Low	- -	2.6	3.32	11.02	10.7	11.24	8.84	9.19	9.44
EV/EBITDA Average	- -	3.33	2.28	15.83	18.84	29.45	15.78	17.4	16.96
EV/EBITDA High	- -	3.33	2.28	18.9	22.09	31.13	18.15	18.72	18.71
EV/EBITDA Low	- -	3.33	2.28	13.89	16.84	27.07	13.95	16.1	14.37
EV/EBIT Average	- -	3.41	2.3	16.05	19.14	29.63	15.78	17.4	17
EV/EBIT High	- -	3.41	2.3	19.16	22.44	31.32	18.15	18.72	18.75
EV/EBIT Low	- -	3.41	2.3	14.09	17.12	27.24	13.95	16.1	14.4
Last Price	- -	- -	- -	50.05	39.85	39.52	28.09	25.51	38.64
High Price	- -	- -	- -	56.5	53.23	44.75	39.92	31.66	41.24
Enterprise Value Average	- -	4,659	6,028	26,655	27,385	27,344	23,541	22,493	26,511
Enterprise Value High	- -	4,659	6,028	31,815	32,106	28,902	27,084	24,199	29,249
Enterprise Value Low	- -	4,659	6,028	23,392	24,487	25,135	20,818	20,805	22,458

Shares Outstanding	- -	351	351	388	433	443	447	446	429
Diluted Weighted Avg Shares	354	354	354	388	415	438	603	594	564
Basic Weighted Avg Shares	354	354	354	388	415	438	448	446	429
Revenue per Share	4.51	5.07	5.12	5.47	5.52	5.11	5.26	5.08	5.55
EBITDA per Share	2.75	3.95	7.47	4.34	3.5	2.12	3.33	2.9	3.65
Operating Income per Share	2.65	3.85	7.41	4.28	3.45	2.11	3.33	2.9	3.64
Basic EPS, GAAP	3.42	3.89	6.63	2.51	1.49	0.1	2.54	1.93	1.8
Basic EPS from Cont Ops	3.79	4.29	6.95	4.38	2.99	0.53	3.8	2.98	3.09
Diluted EPS, GAAP	3.42	3.89	6.63	2.51	1.49	0.1	1.88	1.45	1.37
Diluted EPS from Cont Ops	3.79	4.29	6.95	4.38	2.99	0.53	2.82	2.24	2.35
Dividend per Share	2.08	2.3	2.09	1.03	0.69	0.76	0.8	0.84	0.88
Cash Flow per Share	4	4.57	4.71	5.24	4.86	4.9	6.68	6.21	5.81
Free Cash Flow per Basic Share	4	4.57	4.71	5.24	4.86	4.9	6.68	6.21	5.81
Cash & Equivalents per Share	- -	6.74	2.24	6.83	6.76	5.54	2.76	3.97	3.48
Book Value per Share	- -	12.7	17.24	4.95	5.44	4.49	5.62	6.38	5.5
Tangible Book Value per Share	- -	12.64	17.19	25.42	24.69	21.75	22.53	23.19	20.51

Royalty Pharma plc

Profitability (USD)

Credit (USD)

Liquidity (USD)

Working Capital (USD)

Enterprise Value (USD)

Multiples (USD)

Per Share Data Items (USD)